Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manabu Morimoto

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Diagnostics (Basel, Switzerland)|May 27, 2026
Feasibility of Peroral Pancreatoscopy Using the 9-Fr eyeMAX for Surgical Planning in Main-Duct and Mixed-Type Intraductal Papillary Mucinous NeoplasmsHaruo Miwa, Kuniyasu Irie, Tomoko Fujiyoshi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]Toru Aoyama, Masaaki Murakawa, Keisuke Kazama, et al.
Pancreas|February 4, 2020
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic CancerSatoshi Kobayashi, Makoto Ueno, Masafumi Ikeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2024
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter studyYing Zhang, Kazushi Numata, Kento Imajo, et al.
Liver Cancer|November 1, 2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Masatoshi Kudo, Richard S Finn, Manabu Morimoto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Plos One|September 8, 2018
Prediction model for pancreatic cancer risk in the general Japanese populationMasahiro Nakatochi, Yingsong Lin, Hidemi Ito, et al.
Hepatology International|July 4, 2024
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaMakoto Chuma, Haruki Uojima, Hidenori Toyoda, et al.
Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 11, 2021
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Haruki Uojima, Nobuhiro Hattori, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Diagnostics (Basel, Switzerland)|May 27, 2026
Feasibility of Peroral Pancreatoscopy Using the 9-Fr eyeMAX for Surgical Planning in Main-Duct and Mixed-Type Intraductal Papillary Mucinous NeoplasmsHaruo Miwa, Kuniyasu Irie, Tomoko Fujiyoshi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]Toru Aoyama, Masaaki Murakawa, Keisuke Kazama, et al.
Pancreas|February 4, 2020
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic CancerSatoshi Kobayashi, Makoto Ueno, Masafumi Ikeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2024
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter studyYing Zhang, Kazushi Numata, Kento Imajo, et al.
Liver Cancer|November 1, 2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Masatoshi Kudo, Richard S Finn, Manabu Morimoto, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Plos One|September 8, 2018
Prediction model for pancreatic cancer risk in the general Japanese populationMasahiro Nakatochi, Yingsong Lin, Hidemi Ito, et al.
Hepatology International|July 4, 2024
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaMakoto Chuma, Haruki Uojima, Hidenori Toyoda, et al.
Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 11, 2021
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Haruki Uojima, Nobuhiro Hattori, et al.
Pageof 16